

**AREV Nutrition Sciences Inc.**  
440 – 890 West Pender Street  
Vancouver, B.C. V6C 1J9

## **NEWS RELEASE**

### **AREV NUTRITION SCIENCES INC. ANNOUNCES SHARE ISSUANCE AND PUBLICATION OF CANADIAN SECURITIES EXCHANGE LISTING STATEMENT**

January 10, 2017 – Vancouver, British Columbia – AREV Nutrition Sciences Inc. (the “Company” or “AREV”) (CSE: GNS) is pleased to announce that as of December 9, 2016, it has issued 5,700,000 common shares of the Company pursuant to agreements entered into with Mr. Mike Withrow, Mr. Stephane Maher and Dr. Nils Rehmman. The total share capitalization of AREV as of the date of this news release is 11,913,200 common shares. The distribution of the 5,700,000 common shares of the Company issued on December 9, 2016 is described below.

AREV issued 2,000,000 common shares to Mr. Withrow as partial consideration for vending unique equipment apparatus for extracting oils from natural biomass using fast freezing extraction methods (the “FFE Equipment”) to the Company. The 2,000,000 common shares were issued at a deemed price of \$0.05 per share and accounted for a total of \$100,000. The FFE Equipment had a market value of \$400,000.

AREV issued a convertible debenture with a principal amount of \$300,000 to Mike Withrow representing the remainder of the consideration owed to Mr. Withrow for the FFE Equipment (the “FFE Convertible Debenture”). The FFE Equipment had a market value of \$400,000.

AREV issued a convertible debenture with a principal amount of \$115,000 to Mike Withrow in return for Mike Withrow accepting the convertible debenture as full forgiveness for a credit facility in which AREV was indebted to Mike Withrow. (the “Credit Facility Convertible Debenture”). The principal amount of \$115,000 of the Credit Facility Debenture was determined by the balance of the credit facility indebtedness owed to Mike Withrow.

AREV issued 1,500,000 common shares to Mr. Withrow as consideration for assigning the Company patent rights for a Method and Composition for Preventing and Treating Avian Influenza in Poultry, for which Letters Patent of the United States issued on December 23, 2014, U.S. Patent No. 8,916,211 (the “Poultry Patent.”).

AREV issued 1,500,000 common shares to Mr. Maher as consideration for vending rights to four coconut oil and whey protein derived natural health products (the “COCO-MULSION Products”) to the Company.

AREV issued 500,000 common shares to Mr. Maher pursuant to a signing bonus in a consulting contract between the Company and Mr. Maher.

AREV issued 200,000 common shares to Dr. Rehmman pursuant to a signing bonus in a consulting contract between the Company and Dr. Rehmman.

Further details regarding the share issuance and transactions are available in the Company’s Form 2A – Listing Statement published as of on AREV’s Canadian Securities Exchange Company

Profile on December 22, 2016.

The current members of the board of directors of the Company are Mr. Stephane Maher, Mr. Mike Withrow, Dr. Nils Rehmann and Mr. Scott McDermid.

Mr. Stephane Maher became director, Chief Executive Officer and Interim Chief Financial Officer of AREV on March 29, 2016. He holds a B.A. in Communication with a minor in Marketing from Laval University. Mr. Maher is an independent contractor of the Company. Mr. Maher founded Yellow Brick Sales and Marketing Group Inc. (“Yellow Brick”) in 2002, and has served as President of Yellow Brick since that time. Yellow Brick is a consulting company that helps manufacturers, importers and retailers of natural health products to achieve regulatory compliance in Canada. Yellow Brick is not an affiliate of AREV. Through his work at Yellow Brick, Mr. Maher has gained extensive experience in the nutraceutical industry – particularly with respect to the regulatory regime that applies to the production, importation, manufacture, distribution and sale of natural health products in Canada. Mr. Maher is not an independent director as he currently serves as Chief Executive Officer and interim Chief Financial Officer of the Company.

Mr. Mike Withrow became a director and Chairman of the Board of Directors of the Company on November 13, 2016. Mr. Withrow served as Chief Executive Officer of Arcturus Growthstar Technologies Inc. from May 2015 to August 2016 and as Chief Executive Officer of Abattis Bioceuticals Corp. from February 2011 to February 2015. Mr. Withrow has been involved in early stage structuring and development of bio-tech and nutraceutical companies over the past 10 years. During this time, Mr. Withrow served as Vice President of Business Development of two nutraceutical companies with commercialized products in the market. He has an in-depth knowledge of Intellectual Property and the patent process, supplement innovation, ingredients and is well connected in the ingredients and natural health product industry and vast network of professionals in the medicinal botanical industry. Mr. Withrow serves as a Board Member of the Saskatoon Berry Council of Canada, and brings with him with over 25 years experience in public markets. Mr. Withrow is a control person of the Company and currently serves as Chairman of the Board of Directors of the Company. Mr. Withrow is not an independent director of the Company as he is Chairman of the Board of Directors of the Company and is a control person of the Company.

Dr. Nils Rehmann became a director of the Company on March 29, 2016. He holds a Ph.D. in Pharmacology and Toxicology from the University College Dublin, Ireland, and a Chem.-Eng. Degree from the University of Applied Sciences Fresenius, Germany. Dr. Rehmann works part-time for AREV. He devotes as much time as is necessary to fulfill his obligations to the Company. Dr. Rehmann is an independent contractor of the Company. Since 2013, Dr. Rehmann has owned and operated Nirem Consulting Inc. (“NiRem”), a consulting company that advises clients in the biotechnology, research and development, and life sciences sectors on methods to improve laboratory performance, business development and regulatory compliance, and assisting firms in achieving accreditation under International Standards Organization (ISO) and Good Manufacturing Practices (GMP). Prior to founding NiRem, from 2008 to 2013, Dr. Rehmann worked as a method development chemist for the Research and Productivity Council of New Brunswick (“RPCNB”). In this role, he was involved in developing nutritional labelling analysis and food safety regulatory analysis methods. In his roles at NiRem and RPCNB, Dr. Rehmann has gained extensive experience in the nutraceutical industry – particularly with respect to the regulatory regime that applies to the nutritional labelling and safety accreditation of natural health products in Canada. Dr. Rehmann’s educational background and work experience has also provided him with insight into methods to improve research strategies and laboratory

performance involved in the development of nutraceutical products. Dr. Rehmann is an independent director of the Company.

Mr. Scott McDermid became a director of the Company on November 10, 2016. Mr. McDermid currently serves as a director of Arcturus Growthstar Technologies Inc. and has served in that capacity since September 2015. Mr. McDermid is a businessman with over 30 years of experience in the real estate industry. He is a licensed commercial realtor and has extensive knowledge in the building and property management business. He is also a licensed property manager as well as a licensed builder. Mr. McDermid is an independent director of the Company.

The current members of the audit committee of the Company are Mr. Maher, Dr. Rehmann and Mr. McDermid.

Mr. Maher is not an independent director of the Company as he currently serves as Chief Executive Officer and interim Chief Financial Officer of the Company. Mr. Maher has been a member of the audit committee of the Company since March 29, 2016.

Dr. Rehmann is an independent director of the Company. Dr. Rehmann has been a member of the audit committee of the Company since July 28, 2016.

Mr. McDermid is an independent director of the Company. Mr. McDermid has been a member of the audit committee of the Company since November 11, 2016.

For further information, contact Stephane Maher at 604.868.5013.

On behalf of the Board,

**AREV Nutrition Sciences Inc.**

*“Stephane Maher”*

CEO and Director

*The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and have neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under applicable securities laws.*